Catalog No.
Product Name
Application
Product Information
Citations
-
Caspase-1 Inhibitor
CZL55 is a potent inhibitor of caspase-1, exhibiting an IC50 value of 24 nM. It plays a crucial role in modulating inflammatory pathways and apoptosis, making it valuable for studies related to febrile seizures (FS). This compound is useful for researchers investigating the underlying mechanisms of caspase-1 mediated processes in various pathological conditions. -
Caspase3 Inhibitor
(Rac)-M826 is a selective and reversible inhibitor of caspase-3, exhibiting an IC50 value of 0.005 μM. This compound effectively inhibits apoptosis in NT2 cells, making it a valuable tool for research into nervous system diseases. Its specificity for caspase-3 positions it as a significant reagent for studies related to cell survival and neurodegenerative conditions. -
Caspase Inhibitor
Z-Asp-CH2-DCB is an irreversible inhibitor targeting caspases, with broad-spectrum activity against proteases possessing caspase-like functions. This compound effectively blocks the production of pro-inflammatory cytokines such as IL-1β, TNF-α, IL-6, and IFN-γ in staphylococcal enterotoxin B-stimulated peripheral blood mononuclear cells, while also reducing SEB-induced T-cell proliferation in a dose-dependent manner. Additionally, Z-Asp-CH2-DCB mitigates SU5416-induced septal cell apoptosis and the development of emphysema, making it a valuable tool in apoptosis and inflammatory research applications. -
Caspase-10 Inhibitor
Z-AEVD-FMK is a specific inhibitor of caspase-10, playing a critical role in the regulation of apoptosis. By inhibiting caspase-10, Z-AEVD-FMK effectively prevents the activation of Bid and the subsequent release of apoptosis-inducing factor (AIF) from mitochondria. This action leads to a notable reduction in apoptotic cell populations, making it a valuable tool for investigating apoptotic pathways and potential therapeutic interventions in related diseases. -
Apoptosis Inducer
3-O-Methylgallic acid, a potent apoptosis inducer, is an anthocyanin metabolite known for its significant antioxidant properties. It effectively inhibits the proliferation of Caco-2 cells with an IC50 value of 24.1 μM, demonstrating its potential in cancer research. This compound is valuable for studying apoptotic pathways and therapeutic strategies in oncology. -
Caspase Activator
5,7-Dihydroxychromone functions as a caspase activator and exhibits neuroprotective properties by activating the Nrf2/ARE signaling pathway. This compound effectively mitigates oxidative stress and apoptosis induced by 6-hydroxydopamine (6-OHDA) in SH-SY5Y cells. Additionally, 5,7-Dihydroxychromone reduces the expression of activated caspase-3, caspase-9, and cleaved PARP, making it a valuable tool for studying neuroprotection and apoptosis in cellular models. -
Caspase-9 Fluorogenic Substrate
Ac-LEHD-AMC is a fluorogenic substrate specifically designed for the detection of caspase-9 activity. Upon hydrolysis by caspase-9, Ac-LEHD-AMC releases the AMC fluorophore, which emits fluorescence detectable at an excitation wavelength of 341 nm and an emission wavelength of 441 nm. This substrate is ideal for quantifying caspase-9 activity in various biological samples, facilitating research in apoptosis and related signaling pathways. -
Caspase-3 Activator
Raptinal is a potent activator of caspase-3, directly initiating the intrinsic pathway of caspase-dependent apoptosis. By rapidly inducing cell death in cancer cells through the direct activation of effector caspase-3, Raptinal effectively bypasses the need for initiator caspase-8 and caspase-9 activation. This unique mechanism makes Raptinal a valuable tool for research in cancer therapy and apoptosis studies. -
Caspase Inhibitor
Z-VAD is an irreversible pan-caspase inhibitor that targets multiple caspases, including caspase-3, -6, -7, -8, and -9, while exhibiting a lesser inhibitory effect on caspase-2. This compound is utilized in research for its ability to block apoptosis signaling pathways, promote autophagy and necrosis in tumor cells, and exhibit anti-angiogenic properties. Z-VAD enhances the sensitivity of breast and lung cancer cells to radiotherapy, both in vitro and in vivo, and extends growth delay in tumor xenograft models. It is primarily employed in studies focused on cancer radiosensitization and the regulation of cell death pathways. -
Caspase 8 Inhibitor
Caspase 8 Inhibitor CASP8-IN-1 (Compound 63-R) selectively inhibits caspase 8 with an IC50 value of 0.7 μM. This compound is effective in blocking FasL-induced apoptosis in Jurkat cells, making it a valuable tool for studying apoptotic signaling pathways and cellular responses to death stimuli. Its specificity and potency make CASP8-IN-1 suitable for research applications in cancer biology and therapeutic development targeting caspase-mediated cell death. -
Apoptosis Inducer
Glaucocalyxin A is an ent-kauranoid diterpene derived from Rabdosia japonica var. This compound acts as an apoptosis inducer by inhibiting the nuclear translocation of Five-zinc finger Glis 1 (GLI1), effectively modulating the PI3K/Akt signaling pathway. Its notable antitumor properties make Glaucocalyxin A a valuable reagent for research in cancer biology, particularly in studies focused on osteosarcoma. -
Apoptosis Inducer
Polygalacin D3 is a triterpenoid saponin extracted from the roots of the balloon flower and acts as an apoptosis inducer. It demonstrates significant biological activity by inhibiting the proliferation of non-small cell lung cancer (NSCLC) cell lines through the blockade of the PI3K/Akt signaling pathway. Additionally, Polygalacin D3 induces cell cycle arrest and apoptosis, making it a valuable reagent for cancer research applications. -
Apoptosis Inducer
Dehydroxy-oridonin-vinyl ester is a potent apoptosis inducer that targets the PI3K/Akt signaling pathway. This compound demonstrates strong anti-proliferative activity against SU-DHL-6 lymphoma cells, with an IC₅₀ value of 0.12 μM. Dehydroxy-oridonin-vinyl ester selectively induces cell apoptosis while not interfering with cell cycle progression, making it a valuable tool for research in cancer therapy, particularly in the study of lymphoma. -
Apoptosis Inducer
BIBU1361 dihydrochloride is an apoptosis inducer that primarily targets pro-survival pathways, including Akt/mTOR and gp130/JAK/STAT3. This compound effectively promotes apoptosis while inhibiting autophagy, leading to a reduction in pro-inflammatory cytokine levels, particularly IL-6. BIBU1361 dihydrochloride is valuable for research applications focused on cancer therapy and the modulation of inflammatory responses. -
Apoptosis Inducer
DCZ3301 is a potent apoptosis inducer that functions as an aryl-guanidino inhibitor. It effectively inhibits cell proliferation, induces G2/M cell cycle arrest, and facilitates apoptosis. By downregulating PI3K protein expression and inhibiting AKT phosphorylation, DCZ3301 targets the PI3K/AKT signaling pathway, making it a valuable reagent for cancer research. -
Apoptosis Inducer
Licoricidin (LCD) is a potent apoptosis inducer derived from Glycyrrhiza uralensis Fisch, demonstrating significant anti-cancer properties. It effectively inhibits SW480 colorectal cancer cells with an IC50 of 7.2 μM by promoting cell cycle arrest, apoptosis, and autophagy, making it a promising candidate for chemoprevention and chemotherapy. Additionally, Licoricidin suppresses lung metastasis through the inhibition of tumor angiogenesis and lymphangiogenesis, while improving the tumor microenvironment. In osteosarcoma models, Licoricidin enhances the cytotoxic effects of gemcitabine by inactivating the Akt and NF-κB signaling pathways. Furthermore, Licoricidin alleviates UVA-induced photoaging by scavenging reactive oxygen species and inhibiting MMP-1 activity, indicating its potential in topical anti-aging formulations. -
Autophagy/Apoptosis Inducer
Autophagy Inducer 7 is an effective modulator of autophagy and apoptosis, primarily targeting the Akt/mTOR signaling pathway. This compound promotes autophagy by inhibiting pathway activity and downregulating associated proteins, leading to a reduction in DNA synthesis and inducing G0-G1 cell cycle arrest. Additionally, Autophagy Inducer 7 has demonstrated the ability to inhibit tumor cell proliferation, making it a valuable tool for research in cancer biology and therapeutic strategies involving autophagy. -
ASK1 Inhibitor
ASK1-IN-11 is a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1), exhibiting an IC50 of less than 200 nM. This compound also demonstrates inhibitory effects on TNF-α, MYLK/MLCK kinases, and hERG potassium channels. The primary research applications of ASK1-IN-11 include investigations into inflammation-related pathways. -
Apoptosis Inducer
Crebanine is an isoquinoline-like alkaloid that acts as an apoptosis inducer through antagonism of the α7-nAChR, exhibiting an IC50 value of 19.1 μM. This compound suppresses cancer cell proliferation, migration, and invasion while triggering a reactive oxygen species (ROS) burst that promotes apoptosis. Additionally, Crebanine modulates critical signaling pathways including AKT/FoxO3a, NF-κB, and MAPK, and demonstrates antioxidant properties in microglia by reducing ROS and lipid peroxidation. With applications in studying hepatocellular carcinoma, cerebral ischemia, and Alzheimer's disease, Crebanine may also ameliorate cognitive deficits and ischemia-reperfusion brain damage in rodent models. -
RIPK1 PROTAC Degrader
R1-ICR-5 is a selective RIPK1 PROTAC degrader designed to mediate protein degradation via the VHL pathway. This compound promotes the degradation of RIPK1, subsequently dysregulating TNFR1 and TLR3/4 signaling pathways, enhancing the activity of NF-κB, MAPK, and IFN signaling. Additionally, R1-ICR-5 facilitates RIPK3 activation, leading to necroptosis. This reagent is applicable in research focused on triple-negative breast cancer and skin inflammation. -
Apoptosis Inducer
Alphitolic acid, an apoptosis inducer, is a triterpene isolated from Quercus aliena. It functions by inhibiting Akt–NF-κB signaling pathways, promoting apoptosis and autophagy. Additionally, Alphitolic acid exhibits anti-inflammatory properties by down-regulating nitric oxide and TNF-α production. This compound is applicable in cancer and inflammation research. -
Apoptosis Inducer
Tributyrin, a triglyceride variant of butyric acid, functions as a stable proagent that induces apoptosis. Upon diffusion through biological membranes, it is metabolized by intracellular lipases to release butyrate, which exerts significant antiproliferative and pro-apoptotic effects within cells. This compound serves as a valuable reagent for research into cell differentiation and apoptosis pathways. -
PKD Inhibitor
BPKDi is a potent inhibitor of Protein Kinase D (PKD), targeting PKD1, PKD2, and PKD3 with IC50 values of 1 nM, 9 nM, and 1 nM, respectively. This compound effectively disrupts signal-dependent phosphorylation and nuclear export of class IIa histone deacetylases (HDACs) in cardiomyocytes, consequently attenuating cellular hypertrophy. BPKDi serves as a valuable tool for investigating the role of PKD in cardiovascular research and therapeutic interventions. -
PROTAC Glutathione Peroxidase Degrader
NC-R17 is a non-covalent degrader targeting Glutathione Peroxidase 4 (GPX4) through the PROTAC mechanism, designed to induce ferroptosis in cancer cells. Exhibiting significant antitumor activity, NC-R17 facilitates the targeted degradation of GPX4, contributing to research in cancer biology and therapeutic strategies. The compound combines a Demethyl-RSL3 ligand for GPX4 with an E3 ubiquitin ligase ligand derived from Lenalidomide, connected by a specific PROTAC linker to enhance its biological activity. -
Ferroptosis/Apoptosis Inducer
Lepadin H is a potent ferroptosis and apoptosis inducer, demonstrating significant in vitro cytotoxicity and in vivo antitumor efficacy against cancer cells. This compound functions by decreasing the levels of GPX4 and SLC7A11, while enhancing p53 and ACSL4 expression. Lepadin H promotes the generation of lipid hydroperoxides and increases reactive oxygen species (ROS), leading to a reduction in cellular glutathione (GSH) levels and lipid peroxidation. Additionally, it causes G2/M phase cell cycle arrest and inhibits the clonogenic growth and migration of melanoma cells, making it a valuable tool for cancer research. -
GPX4 Degrader
GDCNF-11 is a potent HIM-PROTAC degrader targeting GPX4, utilizing the chaperone protein HSP90 to facilitate degradation. This compound promotes the ubiquitination of GPX4, leading to reduced expression levels, which in turn induces ferroptosis in HT-1080 cells. GDCNF-11 has a DC50 value of 0.08 μM, making it a valuable tool for studying ferroptosis and GPX4-related pathways in various biological research applications. -
GPX4 Targeting AUTAC
GPX4-AUTAC is a GPX4-targeting autophagy-mediated degrader designed to selectively induce degradation of GPX4 through autophagy. By promoting the ubiquitination of GPX4 via E3 ligase TRAF6, it enhances the interaction with p62, facilitating the autophagy-dependent degradation process. GPX4-AUTAC has been shown to significantly induce ferroptosis and exhibit notable anti-cancer activity in breast cancer cells, breast cancer-derived organoids, and in the MDA-MB-231 tumor xenograft model. Additionally, it demonstrates potent synergistic effects when used in combination with drugs such as Sulfasalazine or traditional chemotherapy agents like Paclitaxel or Cisplatin. -
Glutathione Peroxidase Mimic
Ebselen derivative 1 is a potent glutathione peroxidase (GPx) mimic with oral activity, designed to provide protective effects against oxidative damage. It exhibits significant protective capabilities against cisplatin-induced hair cell (HC) damage, effectively mitigating oxidative stress, apoptosis, and ferroptosis in hair cells. This compound serves as a valuable tool for research into cisplatin-induced hearing loss and related oxidative stress pathways. -
GPX4 Inhibitor
GPX4-IN-11 is a potent inhibitor of GPX4, demonstrating a KD of 45.7 μM. This compound is significant in the study of ferroptosis, enabling researchers to investigate the mechanisms underlying oxidative stress and cell death. Its utility in various biological assays contributes to the understanding of GPX4's role in disease processes and potential therapeutic approaches. -
GPX4 Inhibitior
GPX4-IN-18 is a ferrocene-containing inhibitor targeting glutathione peroxidase 4 (GPX4), recognized for its role in inducing ferroptosis. This compound significantly elevates reactive oxygen species (ROS) and malondialdehyde (MDA) levels in OS-RC-2 clear cell renal carcinoma cells, demonstrating potent biological activity. In HT-1080 cells, GPX4-IN-18 exhibits an IC50 of 0.007 μM in the absence of ferrostatin-1, and 1.486 μM when ferrostatin-1 is present. Additionally, GPX4-IN-18 has been shown to reduce tumor volume and intratumoral GPX4 levels in xenograft models, making it a valuable tool for researching ferroptosis-related pathways. -
GPX4 Inhibitor
GPX4-IN-13 is a potent inhibitor of GPX4, targeting its role in cellular antioxidant defense mechanisms. This compound exhibits significant anticancer activity by promoting ferroptosis and reducing proliferation in thyroid cancer cells. It demonstrates inhibitory effects on the growth of various thyroid cancer cell lines, with IC50 values of 8.39 μM for N-thy-ori-3-1, 10.28 μM for MDA-T32, and 8.18 μM for MDA-T41. GPX4-IN-13 is instrumental for research in cancer biology and therapeutic development targeting GPX4-dependent pathways. -
GPX4 Inhibitor
GPX4-IN-12 is a non-covalent inhibitor of Glutathione Peroxidase 4 (GPX4), primarily targeting this enzyme to induce ferroptosis. This compound effectively inhibits cell proliferation in HT1080 cells, making it a valuable tool for studying the mechanisms of ferroptosis and its implications in cancer research. GPX4-IN-12 is suitable for investigations into oxidative stress and related pathways within various biological contexts. -
GPX4 Inhibitor
GPX4-IN-21 is a selective inhibitor of glutathione peroxidase 4 (GPX4), a key regulator in cellular redox homeostasis. This compound effectively induces ferroptosis by downregulating ferroptosis-related proteins, including SLC7A11, SLC11A2, and GPX4, leading to increased levels of reactive oxygen species (ROS) and malondialdehyde (MDA). GPX4-IN-21 demonstrates significant anti-proliferative activity and is useful for investigating therapeutic strategies in cancer research, particularly in models of melanoma. -
GPX4 Degrader
GPX4 degrader-1 (Compound RS-1) is a hydrophobic tagging (HyT)-mediated degrader specifically targeting GPX4, exhibiting a DC50 value of 8.9 nM in HT1080 cells. This compound effectively induces GPX4 degradation, promoting ferroptosis through the accumulation of lipid reactive oxygen species (ROS). Additionally, GPX4 degrader-1 has shown significant antitumor efficacy in preclinical murine mammary carcinoma models, making it a valuable tool for cancer research and therapeutic study. -
GPX4 PROTAC Degrader
PROTAC GPX4 degrader-4 selectively targets GPX4, functioning as a PROTAC degrader with a DC50 of 5.32 nM. This compound effectively inhibits the proliferation of RT4, T24, and J82 bladder cancer cell lines, exhibiting IC50 values of 0.09, 2.97, and 7.58 μM, respectively. PROTAC GPX4 degrader-4 promotes the accumulation of lipid reactive oxygen species (ROS) and triggers ferroptosis in T24 and RT4 cells. Additionally, it demonstrates significant antitumor efficacy in a T24 tumor-bearing BALB/c nude mouse model, making it a valuable tool for bladder cancer research. -
Apoptosis Inducer
α-Eleostearic acid is a conjugated linolenic acid that functions as an apoptosis inducer, demonstrating its role in prompting programmed cell death. Additionally, it acts as a ferroptosis inducer, contributing to a unique mechanism of cell death associated with iron metabolism. This compound exhibits notable antioxidant properties and displays antitumor activity, making it a valuable reagent for research in cancer biology and cell death mechanisms. -
GPX4 Activator
GPX4 Activator 1 is an allosteric modulator that targets GPX4, demonstrating a Kd of 5.86 μM and an EC50 of 19.19 μM. This compound effectively enhances GPX4 activity, thereby inhibiting ferroptosis by preventing the accumulation of intracellular lipid peroxides induced by ferroptosis inducers. It serves as a valuable tool for researchers studying ferroptosis mechanisms and potential therapeutic interventions in diseases associated with oxidative stress. -
GPX4 Inhibitor
NPD4928 is a potent GPX4 inhibitor that enhances RSL3-dependent ferroptosis through its unique mechanism of action. By binding to ferroptosis suppressor protein 1 (FSP1), NPD4928 effectively inhibits its enzymatic activity, thereby promoting ferroptotic cell death. This compound is valuable for research applications focused on studying ferroptosis pathways and identifying potential therapeutic targets in cancer and neurodegenerative diseases. -
GPX4 Inhibitor
GPX4-IN-6 is a covalent inhibitor of GPX4, exhibiting an IC50 of 0.13 μM. This compound effectively induces ferroptosis, making it a valuable tool for studying mechanisms related to triple-negative breast cancer (TNBC). Its role in modulating oxidative stress pathways presents significant implications for cancer research and therapeutic development. -
GPX4 Inhibitor
JKE-1716 is a potent and selective inhibitor of glutathione peroxidase 4 (GPX4). It induces ferroptosis through the covalent modification of GPX4, making it a valuable tool for studying iron-dependent cell death mechanisms. This compound is applicable in research focusing on cancer biology, neurodegenerative diseases, and oxidative stress-related studies. -
GPX4 Inhibitor
RSL3-NH2 is a selective inhibitor of GPX4, a crucial regulator of lipid peroxidation and ferroptosis. By promoting ferroptosis in cancer cells, RSL3-NH2 serves as an effective tool for studying cell death pathways and cancer metabolism. Additionally, this compound can be utilized as a cytotoxic payload in the development of antibody-drug conjugates (ADCs), enhancing targeted therapeutic strategies in cancer research. -
GPX4 Inhibitor
GPX4-IN-9 is a selective inhibitor of glutathione peroxidase 4 (GPX4), effectively promoting ferroptosis under both in vitro and in vivo conditions. This compound demonstrates significant cytotoxic effects on pancreatic cancer cells, making it a valuable tool for cancer research. Its mechanisms of action offer insights into the role of GPX4 in cancer cell survival and potential therapeutic strategies targeting ferroptosis. -
GPX4 Inhibitor
GPX4-IN-19 is a potent inhibitor of GPX4, exhibiting an IC50 of 0.311 μM through covalent binding to the Sec 46 site. This compound demonstrates significant anti-proliferative effects with a high selectivity for inducing ferroptosis, characterized by intracellular Fe2+ accumulation and elevated levels of lipid peroxides (LPOs) and reactive oxygen species (ROS). GPX4-IN-19 is particularly relevant for research in Triple-Negative Breast Cancer (TNBC), as it induces ferroptosis and subsequent DNA damage. -
YAP-GPX4 Signaling Modulator
Pipecolic acid is a metabolite of lysine that acts as a YAP-GPX4 signaling modulator. It exhibits antioxidant properties and has been shown to reduce retinal vascular tube formation while mitigating ferroptosis. This compound enhances voltage-sensitive Ca2+ channel currents and can induce neuronal apoptosis, making it a valuable tool for research on diabetic retinopathy. Its ability to cross the blood-brain barrier further supports its application in neurological studies. -
Nrf2-Gpx4 Activator
Gingerenone A is an Nrf2-Gpx4 activator that triggers ferroptosis in liver tissue, demonstrating significant potential for therapeutic intervention in liver damage. This compound exhibits notable anti-inflammatory, anti-diabetic, anti-tumor, and pro-aging properties observed in murine models, making it valuable for research in oxidative stress regulation and associated diseases. Its oral bioactivity further enhances its applicability in in vivo studies. -
GPX4 Inhibitor
JKE-1674 is a potent inhibitor of glutathione peroxidase 4 (GPX4), functioning through modulation of cellular redox status. This orally active compound, an analog of ML-210 with a structural modification to the nitroisoxazole ring, demonstrates strong cytotoxicity against LOX-IMVI cells, akin to that of ML-210. Notably, cell viability is restored upon treatment with ferroptosis inhibitors, underscoring its utility in studying ferroptotic cell death pathways and oxidative stress in various biological contexts. -
GPX4 Inhibitor
GPX4-IN-3 is a selective inhibitor of glutathione peroxidase 4 (GPX4), serving as a potent inducer of ferroptosis. At a concentration of 1 μM, GPX4-IN-3 demonstrates 71.7% inhibition of GPX4 activity. This compound is valuable for research applications focused on oxidative stress, cell death mechanisms, and potential therapeutic strategies against various cancers and neurodegenerative diseases. -
GPX4 Inhibitor
GPX4-IN-5 is a potent covalent inhibitor of GPX4, exhibiting an IC50 of 0.12 μM. This compound induces ferroptosis, demonstrating significant anti-tumor activity. GPX4-IN-5 is particularly relevant for research applications focused on triple-negative breast cancer (TNBC). -
MDM2-MDM4 Inhibitor
MMRi62 is an MDM2-MDM4 inhibitor that promotes ferroptosis by targeting negative regulators of the tumor suppressor p53. It exhibits P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induces autophagy. MMRi62 augments reactive oxygen species levels and triggers lysosomal degradation of ferritin heavy chain (FTH1), while also facilitating the proteasomal degradation of mutant p53. Moreover, MMRi62 demonstrates efficacy in vivo by inhibiting orthotopic xenograft models of PDAC characterized by frequent KRAS and TP53 mutations, supporting its potential in cancer research applications. -
GPX4 Activator
GPX4 Activator 2 is a potent activator of glutathione peroxidase 4 (GPX4), a key enzyme involved in reducing oxidative stress. It demonstrates significant cardioprotective effects and effectively inhibits cellular ferroptosis with an EC50 of 7.8 μM. This compound is valuable for research applications focused on myocardial injury and the mechanisms of ferroptosis in cardiovascular diseases.
